Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.77 |
| ▸ | USP2 | O75604 | 6/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | SLC29A2 | Q14542 | 1/20 | 0.77 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYBB | P04839 | 1/20 | 0.60 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15658933 | 0.92 | MAPT (0.84) | MAPTUSP2POLBSLC29A2SLC29A1 | |
| SCHEMBL15662302 | 0.84 | MAPT (0.80) | MAPTUSP2POLBSLC29A2SLC29A1 | |
| SCHEMBL24019198 | 0.82 | MAPT (0.77) | MAPTUSP2POLBSLC29A2SLC29A1 | |
| SCHEMBL21530456 | 0.80 | ALDH1A1 (0.70) | MAPTUSP2POLBSLC29A2SLC29A1 | |
| SCHEMBL24019197 | 0.79 | MAPT (0.77) | MAPTUSP2POLBSLC29A2SLC29A1 | |
| SCHEMBL21530420 | 0.77 | MAPT (0.60) | MAPTUSP2POLBSLC29A2SLC29A1 | |
| SCHEMBL26317590 | 0.77 | MAPT (0.64) | MAPTUSP2POLBSLC29A2SLC29A1 | |
| SCHEMBL18542996 | 0.75 | MAPT (0.80) | MAPTUSP2POLBSLC29A2SLC29A1 | |
| SCHEMBL30100838 | 0.75 | CYBB (1.00) | MAPTUSP2POLBSLC29A2SLC29A1 | |
| SCHEMBL17999762 | 0.75 | CYBB (1.00) | MAPTUSP2POLBSLC29A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9687490-B2 | Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase | GLUCOX BIOTECH AB (SE) | 2017-06-27 | — | — | US | claimed |
| EP-2911667-B1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | GLUCOX BIOTECH AB (SE) | 2017-02-22 | — | — | EP | claimed |
| US-20150283146-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | GLUCOX BIOTECH AB (SE) | 2015-10-08 | — | — | US | claimed |
| EP-2911667-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | Glucox Biotech AB (SE) | 2015-09-02 | — | — | EP | claimed |
| WO-2014064118-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | GLUCOX BIOTECH AB (SE) | 2014-05-01 | — | — | WO | claimed |
| US-9687490-B2 | Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase | GLUCOX BIOTECH AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-9687490-B2 | Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase | GLUCOX BIOTECH AB (SE) | 2017-06-27 | — | — | US | disclosed |
| EP-2911667-B1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | GLUCOX BIOTECH AB (SE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2911667-B1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | GLUCOX BIOTECH AB (SE) | 2017-02-22 | — | — | EP | disclosed |
| US-20150283146-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | GLUCOX BIOTECH AB (SE) | 2015-10-08 | — | — | US | disclosed |
| US-20150283146-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | GLUCOX BIOTECH AB (SE) | 2015-10-08 | — | — | US | disclosed |
| EP-2911667-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | Glucox Biotech AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014064118-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | GLUCOX BIOTECH AB (SE) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014064118-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | GLUCOX BIOTECH AB (SE) | 2014-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283146-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE | PNPO, XDH, DPYD | MAPT 2020/4885USP2 3262/4885POLB 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.